Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 875 results found. Search for [ Serum Institute ]

Results 1 to 21 of 875
Reuters
April 9, 2021
\"The agreement is legally binding and served as a basis for the first-round allocation document, which has been communicated to all participating economies,\" a Gavi spokeswoman said in an email


PTI
April 9, 2021
Despite increased demand for COVID-19 vaccines in India COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year


BusinessToday.In
April 9, 2021
Centre's clarification comes amid an ongoing debate over the export of vaccines with some states, mostly non-BJP ruled, flagging the issue of shortage of vaccines


BusinessToday.In
April 9, 2021
The move by the national committee on adverse effects following immunisation (AEFI) has come after the European's regulator said it found rare cases of blood clots among some adult recipients who were given AstraZeneca-Oxford university's vaccine shots


PTI
April 9, 2021
A growing number of countries have either halted or limited the use of the AstraZeneca coronavirus vaccine recently over fears that it can cause serious blood clots


PTI
April 9, 2021
Treasury has confirmed that the Serum Institute of India has fully refunded us for the remaining 500,000 doses that had not been delivered to South Africa and the money is already in our bank account, Health Minister Zweli Mkhize said


Reuters
April 9, 2021
The Philippines suspended the use of AstraZeneca shots for people under age 60 after Europe's regulator said on Wednesday it found rare cases of blood clots among some adult recipients, although it still believes that the vaccine's benefits outweighed its risks


PB Jayakumar
April 8, 2021
India had administered 9,01,98,673 vaccine doses till today morning, of which eight states accounted for 60 per cent of the total doses. Maharashtra was leading with 89,49,560 doses, accounting for 9.92 per cent of total doses


BusinessToday.In
April 8, 2021
Adar Poonawalla said that SII has submitted a formal proposal for an upfront grant from the government. It is otherwise difficult to ramp up as they have already poured in thousands of crores and borrowed Rs 1,500 crore, he said


BusinessToday.In
New Delhi, April 8, 2021
Serum Institute of India CEO Adar Poonawalla on Tuesday said that the effectiveness of the Covishield vaccine rises to as much as 90 per cent if the two shots are separated by about 2.5-3 months. Speaking to India Today, Poonawalla added that no COVID-19 vaccine is preventing more than 20-30 per cent of recipients from getting the disease. He said that the vaccine acts as a shield, which prevents anyone from going to the hospital and the same applies to different virus mutations. He also said that immunity kicks in one month after taking the first dose of the Covishield vaccine. Watch the video for more.Watch More | Is Covishield safe for people with low immunity? CEO of SII replies


BusinessToday.In
New Delhi, April 7, 2021
CEO of Serum Institute of India Adar Poonawalla spoke to India Today about when the vaccination can be opened up for all. He stated that it was a difficult decision even for the government as the priority was to protect the most vulnerable people and keeping that in mind, vaccinating everyone immediately was not an option. He also shared that for the moment SII had stopped exporting vaccines considering the second wave of the virus that had gripped the nation. Indians were a priority at this hour, he added. Watch the video for more.Also Read: Centre allows COVID-19 vaccination drives at workplaces from April 11


BusinessToday.In
New Delhi, April 7, 2021
Adar Poonawalla, CEO, Serum Institute of India, explains how those suffering from auto-immune disorders and those with compromised immunity may be impacted by the vaccine. The world's largest vaccine maker Serum Institute of India has been supplying doses to not just India but other countries as well. India is in the midst of a second wave of coronavirus but vaccine hesitancy remains a cause for worry.  Watch the video for more.


BusinessToday.In
New Delhi, April 7, 2021
Serum Institute of India CEO Adar Poonawalla cleared the air around Covishield vaccine efficacy and  safety as many people in India are still hesitant to take the vaccine. In an interview with India Today, Poonawalla said that Covishield was absolutely safe and gave 94 percent efficacy. The Oxford-AstraZeneca vaccine produced by Serum Institute in Pune has come under a cloud of suspicion after cases of blood clots were reported in some recipients.  Watch the video for more details.


BusinessToday.In
April 7, 2021
\"We need roughly Rs 3,000 crore which is not a small figure considering we have already spent thousands of crores,\" said Adar Poonawalla


Associated Press
April 7, 2021
SII CEO Adar Poonawalla said the company has \"chosen to prioritize India temporarily for two months\" and hopes to then restart exports by June


BusinessToday.In
April 6, 2021
Adar says Covishield has found an excellent response below the age of 50 with one dose. About 70 per cent of people are fully protected with one dose, but the second dose is necessary for long-term immunity protection, he adds


PTI
April 6, 2021
I've had substantial contact with the Serum Institute. India is blessed with having a major manufacturer of global vaccines in India, World Bank President David Malpass said


BusinessToday.In
March 31, 2021
The Drug Controller General of India (DCGI) has allowed the extension of AstraZeneca coronavirus vaccine's expiration time period from the earlier prescribed six months


Reuters
March 30, 2021
After a slow start, India is picking up the pace of its immunisation campaign as it tries to head off a new surge in infections that has brought the highest tallies of daily cases and deaths in months


Reuters
March 28, 2021
A UNICEF spokeswoman says deliveries of SII/AZ vaccine are expected to begin fully again by May, with catch-up deliveries to reach every participant's full allocation up to May, accelerating thereafter


PAGES 1 OF 44  12345